Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
Mark G LebwohlAndrew BlauveltMartin Alan MenterKim A PappScott GuenthnerRadhakrishnan PillaiRobert J IsraelAbby JacobsonPublished in: American journal of clinical dermatology (2020)
NCT01101100.